News of Note—Merck petition, GeoVax partnership and more


Here is some other vaccine news of note for the week:

> A petition challenging Merck's decision to phase out a RotaTeq supply deal for four African countries has generated nearly 50,000 signatures. Petition | FiercePharma article

> GeoVax signed a partnership with Virometix to develop a therapeutic HPV vaccine. Release

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

> Initial data for NantKwest's cancer vaccine left analysts confused about the candidate's potential benefit. FierceBiotech article

> ImmusanT started a phase 2 study for its celiac disease vaccine. Release (PDF)

> With support from the Gates Foundation, InDevR will apply its VaxArray potency testing platform to measles and rubella vaccines. Release


Suggested Articles

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.